Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Immunocore Holdings Plc ADR (IMCR)

Immunocore Holdings Plc ADR (IMCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,596,106
  • Shares Outstanding, K 50,019
  • Annual Sales, $ 249,430 K
  • Annual Income, $ -55,290 K
  • EBIT $ -61 M
  • EBITDA $ -57 M
  • 60-Month Beta 0.72
  • Price/Sales 6.56
  • Price/Cash Flow N/A
  • Price/Book 4.56

Options Overview Details

View History
  • Implied Volatility 57.91% ( -9.72%)
  • Historical Volatility 38.51%
  • IV Percentile 58%
  • IV Rank 22.55%
  • IV High 109.35% on 05/22/24
  • IV Low 42.93% on 12/15/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 3
  • Volume Avg (30-Day) 40
  • Put/Call OI Ratio 0.59
  • Today's Open Interest 1,936
  • Open Int (30-Day) 5,320

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.38
  • Number of Estimates 7
  • High Estimate -0.18
  • Low Estimate -0.60
  • Prior Year 0.04
  • Growth Rate Est. (year over year) -1,050.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.72 +3.73%
on 10/03/24
35.47 -13.08%
on 10/28/24
-0.30 (-0.96%)
since 09/30/24
3-Month
29.72 +3.73%
on 10/03/24
40.52 -23.91%
on 07/31/24
-9.26 (-23.10%)
since 07/30/24
52-Week
29.72 +3.73%
on 10/03/24
76.98 -59.95%
on 02/01/24
-12.95 (-29.58%)
since 10/30/23

Most Recent Stories

More News
Institutions are Buying These 3 Stocks and Analysts Agree

Rumble (RUM), Immunocore (IMCR), and STMicroelectronics (STM) are attracting increased institutional interest, presenting potential investment opportunities.

STM : 27.14 (-1.49%)
IMCR : 30.83 (-3.38%)
RUM : 5.84 (-1.18%)
Grey Wolf Therapeutics Reports Promising Preclinical Data from Research Collaboration with Immunocore in Oral Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023

/PRNewswire/ -- Grey Wolf Therapeutics, a biotechnology company focused on generating entirely novel anti-tumour immune responses through targeted cancer...

IMCR : 30.83 (-3.38%)
Is Biotech Immunocore About To Make A 25% Price Move?

Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher.

IMCR : 30.83 (-3.38%)
AMGN : 320.16 (+1.46%)
GILD : 88.82 (+0.60%)
REGN : 838.20 (-9.17%)
VRTX : 475.98 (+0.19%)
MRNA : 54.36 (-0.66%)
EXAS : 68.93 (-2.17%)
ARKK : 45.89 (-4.85%)
LLY : 829.74 (-2.02%)
GSK : 36.76 (-0.68%)
IBBQ : 23.20 (-1.65%)
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?

Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.

NBIX : 120.27 (-3.27%)
MDY : 565.60 (-1.32%)
CPRX : 21.80 (+1.11%)
AVEO : 15.00 (unch)
IMCR : 30.83 (-3.38%)
AMGN : 320.16 (+1.46%)
VRTX : 475.98 (+0.19%)
REGN : 838.20 (-9.17%)
GILD : 88.82 (+0.60%)
Medison Pharma Announces Expansion of the Multi-Territorial Agreement with Immunocore into Latin America

/CNW/ -- Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets,...

IMCR : 30.83 (-3.38%)
Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update

Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp) now approved in over 30 countries with...

IMCR : 30.83 (-3.38%)
Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022

Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.,...

IMCR : 30.83 (-3.38%)
Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022

Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical...

IMCR : 30.83 (-3.38%)
Immunocore Announces $140 Million Private Placement Financing

PRESS RELEASE Immunocore Announces $140 Million Private Placement Financing (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 18...

IMCR : 30.83 (-3.38%)
What's Winning in 2022? 3 Stocks That Are Doing Fine

Immunocore, Axsome Therapeutics, and Takeda are significantly outperforming the market this year.

IMCR : 30.83 (-3.38%)
AXSM : 89.03 (-0.48%)
TAK : 13.94 (+0.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Immunocore Holdings plc is a late-stage biotechnology company. It engages in development of a novel class of T cell receptor bispecific immunotherapies designed to treat diseases, including cancer, infectious and autoimmune disease. Immunocore Holdings plc is based in Abingdon, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 33.09
2nd Resistance Point 32.52
1st Resistance Point 31.67
Last Price 30.83
1st Support Level 30.26
2nd Support Level 29.69
3rd Support Level 28.84

See More

52-Week High 76.98
Fibonacci 61.8% 58.93
Fibonacci 50% 53.35
Fibonacci 38.2% 47.77
Last Price 30.83
52-Week Low 29.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar